Laurie Tomlinson

Nov 19, 2024 | nature.com | Ruth Costello |Emily Herrett |Amir Mehrkar |Laurie Tomlinson |Christopher T. Rentsch

AbstractBiological evidence suggests ursodeoxycholic acid (UDCA)—a common treatment of cholestatic liver disease—may prevent severe COVID-19 outcomes. We aimed to compare the hazard of COVID-19 hospitalisation or death between UDCA users versus non-users in a population with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

Jun 18, 2024 | academic.oup.com | Keppel Street |Angel Y. S |Laurie Tomlinson |Johannes F E

Cardiovascular disease (CVD) is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial, each prevent CVD. However, trial results may not be generalisable and their effectiveness in underrepresented groups is unclear. Using trial emulation methods within routine-care data to validate findings, we explored generalisability of ONTARGET results.

Feb 23, 2023 | dispatchist.com | Laurie Tomlinson

DispatchistNews from around the globe in real timeClient login£1.7m funding to examine how data can improve population healthProfessor Laurie Tomlinson has been awarded a National Institute for Healthcare Research (NIHR) Research Professorship worth £1.7m to explore how routinely-collected healthcare data can be used to improve clinical guidance.